Arrowhead Pharmaceuticals, Inc.

334 articles with Arrowhead Pharmaceuticals, Inc.

• Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences

  5/31/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

• Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results

  5/8/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 second quarter ended March 31, 2019.

• Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences

  5/2/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

• Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen

  4/24/2019

  Arrowhead Pharmaceuticals Inc. announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by Janssen Pharmaceuticals, Inc. in its ongoing Phase 1/2 study (AROHBV1001) in patients with chronic hepatitis B virus (HBV).

• Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results

  4/24/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2019, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2019 second quarter ended March 31, 2019.

• 

  Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Corners...

  4/17/2019

  Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.

• Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

  4/15/2019

  Arrowhead Pharmaceuticals Inc. announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

• Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™

  4/12/2019

  Arrowhead Pharmaceuticals Inc. presented preclinical data at The International Liver Congress™ 2019, the annual meeting of the European Association for the Study of the Liver, demonstrating that sustained reduction of mutant Z-AAT protein by RNA interference substantially reversed the alpha-1 antitrypsin deficiency disease phenotype in the PiZ mouse model.

• Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™

  4/12/2019

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV), a third-generation subcutaneously administered RNA interference (RNAi) therapeutic candidate being developed as a potential treatment for patients with chronic hepatitis B virus (HBV) infection, at The International Liver Congress™ 2019 (ILC),

• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) - March 29, 2019

  3/29/2019

  Arrowhead Pharmaceuticals Inc. announced that as an inducement to entering into employment with the Company, on March 22, 2018, the Compensation Committee of the Board of Directors approved "inducement" grants to 7 new employees under Rule 5635 of the NASDAQ Marketplace Rules.

• Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

  3/18/2019

  Arrowhead Pharmaceuticals Inc. announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

• Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences

  3/1/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events:

• Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results

  2/7/2019

  Arrowhead Pharmaceuticals Inc. announced financial results for its fiscal 2019 first quarter ended December 31, 2018. The company is hosting a conference call at 4:30 p.m. EST to discuss results.

• Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results

  1/24/2019

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 7, 2019, at 4:30 p.m. EST to discuss its financial results for the fiscal 2019 first quarter ended December 31, 2018.

• Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

  1/7/2019

  Arrowhead intends to proceed with AROAPOC31001, a Phase 1 single and multiple dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ARO-APOC3 in adult healthy volunteers, hypertriglyceridemic patients, and patients with familial chylomicronemia syndrome

• Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases

  1/7/2019

  Arrowhead Pharmaceuticals, Inc. announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 (ANGPTL3) being developed for the treatment of dyslipidemias and metabolic diseases.

• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) on December 7, 2018

  12/17/2018

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018, the Board of Directors approved "inducement" grants to 3 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules.

• Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results

  12/11/2018

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 fourth quarter and year ended September 30, 2018.

• Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

  11/27/2018

  Arrowhead Pharmaceuticals Inc. today announced that it will host a webcast and conference call on December 11, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2018.

• 

  Two Biotechs and One Medtech Make Deloitte’s Top 10 of the 2018 Fast 500 List

  11/16/2018

  Two pharmaceutical companies and a medtech maker snagged three of the top-10 spots on Deloitte’s 2018 North America Technology Fast 500, a ranking of the fastest-growing North American companies in the fields of technology, life sciences, telecommunications, media and energy.